Novo Nordisk (NVO) just reported 2 year results from its evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease - and the market did not like what it saw.<br /><br />The trials, which enrolled 3,808 adults, tested oral semaglutide versus placebo on top of standard of care. Despite improvements in Alzheimer’s-related biomarkers, semaglutide did not show superiority in slowing disease progression on the key CDR-SB cognitive scale.<br /><br />Based on these results, Novo is discontinuing the planned 1 year extension of both studies. The company notes that semaglutide’s safety profile remained consistent with prior trials and highlights more than 37 million patient-years of exposure across diabetes and obesity populations. <br />Benzinga<br /><br />Earlier this morning, NVO shares were trading about 10.7% lower around 42.34 dollars premarket, as investors quickly removed the Alzheimer’s upside from the story. <br />Benzinga<br /><br />Topline data will be presented at the CTAD conference on December 3, 2025, with full results coming at the AD/PD 2026 meeting.
